Proactive Investors - Run By Investors For Investors

Summit Therapeutics welcomes investment from US billionaire ahead of busy Q1

Glyn Edwards, chief executive of Summit Therapeutics PLC (LON:SUMM), discusses with Proactive London's Andrew Scott the recent US$25mln investment in the company by US healthcare entrepreneur Robert Duggan.

Duggan was the chief executive and chairman of Pharmacyclics before it was sold to pharma giant AbbVie Inc (NYSE:ABBV) for US$21bn in 2015.

The purchase will take Duggan’s stake, which sat at just 0.2% before, to 48.8%.

Meet Yellow Cake PLC, Avation PLC, Manolete Partners PLC and Crossword Cybersecurity Plc at our event, London , 05 September 2019. Register here »
View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use